CTAD Asia Alzheimer's Conference is today and tomorrow. Dr. Jeffrey Cummings, from the Resverlogix Neurodegenerative Clinical & Scientific Advisory Board (NCSAB)  delivered the oral presentation "Cognitive evaluation of treatment effects of the bromodomain and extra terminal domain inhibitor apabetalone: Design and baseline data of the cognition substudy of the BETonMACE Phase 3 cardiovascular trial" earlier this morning (way earlier....China time) and he also presented a poster (available here) entitled "Effect of the BET Protein Inhibitor Apabetalone on Serum Markers of Potential Importance for Cognitive Decline in Cardiovascular Disease Patients." See here for full abstracts and program for CTAD Asia.

Dr. Cummings’ is a giant in Alzheimer's research. His contributions and achievements in the field of Alzheimer’s and brain research are significant. We are very fortunate to have this expert on the Resverlogix NCSAB and for him to be presenting/educating this audience at CTAD Asia about the potential of apabetalone for treatment of neurodegenerative diseases. It speaks volumes to me to have this degree of involvement from Dr. Cummings.

https://consultqd.clevelandclinic.org/a-giant-of-alzheimers-research-surveys-the-state-of-his-field/

BearDownAZ